New registry tracks radiation therapy outcomes in metastatic cancer patients
NCT ID NCT06306924
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This registry is collecting information from 2,000 people with metastatic cancer who are receiving radiation therapy as part of their standard care. Researchers will gather clinical data and patient-reported outcomes to better understand how radiation affects cancer outcomes. The goal is to build a foundation for future studies that could improve treatment for metastatic cancer.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Participants
-
About 2,000 people
The number the study aims to enrol. It can still change while the study runs.
- Started
-
Apr 2024
- Expected to finish
-
May 2033
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
Who is studied
Subjects with metastatic cancer receiving palliative radiation therapy at the University of North Carolina Chapel Hill.
- Ages
-
18 years and older
- Sex
-
Anyone
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: Written informed consent was obtained to participate in the study and HIPAA Authorization for release of personal health information. Ability to understand and willingness to sign informed consent Diagnosed with or is suspected to have metastatic cancer. Age ≥ 18 years at the time of consent. Evaluated to receive radiation therapy as part of their standard-of-care treatment plan. Exclusion Criteria: All participants must not meet any of the following exclusion criteria prior to enrollment to participate in this study: Any serious medical or psychiatric disorder that would interfere with the participant's ability to give informed consent.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Cancer are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The places running it
1 site. The list below names each one and where it is.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Locations
-
Lineberger Comprehensive Cancer Center at University of North Carolina, Chapel Hill
RECRUITINGChapel Hill, North Carolina, 27599, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can colorectal surgery patients go home in two days?
- Can a personal navigator help young cancer patients through treatment?
- Can a smartwatch predict which cancer patients return to hospital?
- Two-Drug combo aims to stall advanced breast cancer
- Blood thinner flush could boost tumor biopsy success
- Could a frailty score predict which older cancer patients survive intensive care?